Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI)
Oculometric measures have been shown to be sensitive enough to distinguish between patients with MCI, AD and other dementias (and between the phenotypes of FTD), and sensitive enough to show statistically significant change in less than 12 months (both in MCI, mild AD and moderate AD patients). On top of that, oculometric proxies can separate preclinical AD patients into meaningful phenotypes.
We’re looking to partner with pharma on trials involving AD and MCI outcome measures such as:
- CDR, CDR-SOB and MMSE
- NART IQ, VFT, Digit span test, Spatial Span test, TMT
- MRI measures of regional cortical thickness